PTEN and melanoma: Such an effect seems to occur irrespectively of cancer type and driver mutation, as it has been documented in preclinical models of lung and pancreatic ductal carcinomas driven by KrasG12D (Guo et al, 2013; Rosenfeldt et al, 2013; Rao et al, 2014; Yang et al, 2014), BrafV600E‐driven lung cancer (Strohecker et al, 2013), and melanoma (upon simultaneous loss of Pten) (Xie et al, 2015).